ERBB2 and neoplasm: Thanks to next generation sequencing (NGS) and circulating tumor DNA (ctDNA) studies, the authors also showed the mechanisms of resistance to anti-EGFR drugs, such as the presence of EGF-R negative tumor clones, KRAS mutation/amplifications, PTEN deletion, and NRAS/HER2/MYC amplifications.